The prevalence of metabolic syndrome is rising significantly, driven by factors such as urbanization, movement-deficient lifestyles, and excessive energy consumption. Metabolic syndrome, characterized by multifactorial conditions including obesity, insulin resistance, dyslipidaemia, and hypertension, poses significant challenges in treatment due to its multifactorial nature and systemic effects. Conventional therapeutic approaches for metabolic syndrome frequently face challenges of low bioavailability, off-target effects, and poor patient compliance. Nanoparticles are utilized to enhance treatment effectiveness, reduce side effects, and minimize drug dosage. Their small size, high permeability, and stability enable effective absorption by target organs. Various nanoparticles, differing in usage and particle size, have been studied for this purpose. Advanced nanocarriers, including lipid-based carrier systems like liposomes, polymeric nanoparticles, dendrimers, and lipid-based nanostructures, micelles, and niosomes, reported good efficacy in delivering bioactive molecules to specific tissues, particularly adipose tissue, liver, and vascular endothelium which are the key sites of metabolic syndrome pathology. Functionalization of nanocarriers with ligands like peptides, and antibodies, enhances their ability to selectively attach to overexpressed receptors on diseased cells. Moreover, stimuli-responsive nanomaterials enable controlled drug release in response to pH, temperature, or enzymatic activity, further improving precision. In conclusion, the inclusion of nanotechnology advanced in enhancing the efficacy of various medications. By preventing drug degradation and enabling controlled sustained release, nanotechnology significantly improves drug performance. These advancements not only reduce the required dosage but also minimize side effects, making nanotechnology a valuable tool in the treatment of complex conditions like metabolic syndrome.